Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2018.1503032

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.

Authors

Jonathan G Pol^{1

2

3

4

5}, Sarah Lévesque^{1

2

3

4

5}, Samuel T Workenhe^{6

7

8}, Shashi Gujar^{9

10

11

12}, Fabrice Le Boeuf^{13

14}, Derek R Clements⁹, Jean-Eudes Fahrner^{1

15

16}, Laetitia Fend¹⁶, John C Bell^{13

14}, Karen L Mossman^{6

7

8}, Jitka Fucikova^{17

18}, Radek Spisek^{17

18}, Laurence Zitvogel^{1

15}, Guido Kroemer^{1

2

3

4

5

19

20

21}, Lorenzo Galluzzi^{4

22

23}

Affiliations

¹ Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
² INSERM, Paris, France.
³ Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
⁴ Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
⁵ Université Pierre et Marie Curie/Paris VI, Paris, France.
⁶ McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
⁷ Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.
⁸ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
⁹ Department of Pathology, Dalhousie University, Halifax, NS, Canada.
¹⁰ Department of Microbiology and Immunology, Dalhousie University, NS, Canada.
¹¹ Department of Biology, Dalhousie University, NS, Canada.
¹² Centre for Innovative and Collaborative Health Sciences Research, Quality and System Performance, IWK Health Centre, Halifax, NS, Canada.
¹³ Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
¹⁴ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
¹⁵ INSERM, Villejuif, France.
¹⁶ Transgene S.A., Illkirch-Graffenstaden, France.
¹⁷ Sotio a.c., Prague, Czech Republic.
¹⁸ Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
¹⁹ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
²⁰ Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France.
²¹ Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
²² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
²³ Sandra and Edward Meyer Cancer Center, New York, NY, USA.

Abstract

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Keywords: CAVATAK; DNX-2401; HF10; MV-NIS; Maraba MG1; Pexa-Vec; REOLYSIN; T-VEC.

Publication types

Review
Research Support, Non-U.S. Gov't

Grants and funding

LG is supported by an intramural startup from the Department of Radiation Oncology of Weill Cornell Medical College (New York, US), and by donations from Sotio a.s. (Prague, Czech Republic) and Phosplatin (New York, US). GK is supported by the Ligue contre le Cancer (Equipe labelisée); Agence Nationale de la Recherche (ANR)—Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Médicale (FDM20140630126 and FDM 40739); the European Commission (ArtForce); the European Research Council (ERC); the Leducq Foundation; the Seerave Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).